Navigation Links
Sermo Report Indicates that Ticagrelor is Likely to Affect the Standard of Care for ACS Patients
Date:8/26/2010

CAMBRIDGE, Mass., Aug. 26 /PRNewswire/ -- Sermo (http://www.sermo.com/client), the world's largest online community for physicians, today announced a free Sermo Report titled, "FDA Committee Recommends Approval for Ticagrelor." The report covers physician opinions about the introduction of an investigational oral antiplatelet treatment for acute coronary syndrome (ACS).  According to the results, 46% of physicians feel that ticagrelor will likely affect the current standard of care, Plavix (clopidogrel), for ACS patients. If approved, 57% of physicians said they could switch up to 20% of their patients to ticagrelor.

The Sermo Report polled 60 physicians, many of who also participated in a discussion about the treatment. Acute coronary syndrome (ACS) incorporates a number of symptoms consistent with the probability that a patient is suffering from active Myocardial Infarction. Competitors to ticagrelor include Bristol-Myers Squibb Co. and Sanofi-Aventis', Plavix and Effient, sold by Eli Lilly & Company.

"Physicians on Sermo see ticagrelor as significantly impactful to clinicians," said Adam Sharp, Chief Medical Officer at Sermo. "However, cost and time in market could slow adoption. While more research on physician awareness still needs to be done, it's also interesting to note that 50% of docs did not know about the FDA approval before seeing it on Sermo."

Highlights from the report include:

  • Cost, time in market and generic Plavix were identified as three issues that could dissuade physicians from writing ticagrelor.
  • Reversibility and less post-operative bleeding were identified as possible advantages of this medication over Plavix.

Physicians shared their views of ticagrelor:

"While cost is certainly an issue we deal with all the time (can't wait until Plavix goes generic), there are some advantages with this medication – the biggest being the reversibility. I would be curious to see in the future how cardiac surgeons feel when this drug is in use – will they find that the drug really is reversible and that they find less post-operative bleeding. This would be a clear benefit over Plavix."

--Cardiologist, Sermo physician

"I would wait for a year or two to start prescribing it systematically. This time should be sufficient to elucidate the side-effect profile of the drug."

---Critical Care, Sermo physician

The full Sermo report includes key findings, MD demographics and post analysis.

Download the free report at http://www.sermo.com/client.

About Sermo Reports

Sermo Reports solicit perceptions and opinions from physicians about drugs, devices, treatments, and trends. Data for Sermo Reports are gathered through Sermo Posts, which allow physicians to participate in a poll and discussion about the topic.

About Sermo

Sermo is the largest online physician community, where over 115,000 practicing physicians discuss clinical cases and get advice about drugs and practice management. By leveraging Sermo's social media platform, clients can tap into peer-to-peer dialog and engage MDs to gain market intelligence and increase brand awareness. For more information, visit http://www.sermo.com/clients.


'/>"/>
SOURCE Sermo
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cyberonics Reports Strong Fiscal 2011 First Quarter Results
2. NCPA: AARP Report Finds Brand Name Drug Prices Soar as Large Pharmacy Benefit Managers Reap Windfall Profits
3. Reportlinker Adds Clinical Laboratory Testing Volume 1: Reagents and Instruments
4. Reportlinker Adds Portable and Transport Ventilator Market Shares, Strategies, and Forecasts, Worldwide, 2010 to 2016
5. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
6. Kewaunee Scientific Reports Sales and Earnings for First Quarter
7. Latest BioTrends Report Provides Comprehensive Market Landscape of the Dialysis Vascular Access Market
8. Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
9. Kensey Nash Reports Fourth Quarter and Full Fiscal Year 2010 Financial Results
10. Huifeng Bio-Pharmaceutical Reported Second Quarter 2010 Financial Results and Reaffirms its 2010 Guidance
11. China Yongxin Pharmaceuticals Reports Second Quarter 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/27/2017)... 2017  Commended for their devotion to personalized service, SMP ... number one in the South Florida Business Journal,s 50 Fastest-Growing ... yearly list, the national specialty pharmacy has found its niche.  ... will soon be honored by SFBJ as the 2017 Power ... Set to receive his award in October, Bardisa said of ...
(Date:9/25/2017)... Sept. 25, 2017  EpiVax, Inc., a leader ... and immune-engineering today announced the launch of EpiVax ... of personalized therapeutic cancer vaccines. EpiVax has provided ... access to enabling technologies to the new precision ... lead EpiVax Oncology as Chief Executive Officer. Gad ...
(Date:9/22/2017)... -- AVACEN Medical (AVACEN) announced that its CE-Marked AVACEN ... with the widespread pain associated with fibromyalgia in the ... Essex, England commented, "I had difficulty ... sleep at all, tremendous pain, with every movement sending ... AVACEN 100] enough, how this has and is helping ...
Breaking Medicine Technology:
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... ... DevOps and Agile Software Development, has been awarded a contract by the Center ... Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile methodologies in ...
(Date:10/12/2017)... Del. (PRWEB) , ... October 12, 2017 , ... ... and advisory services for healthcare compliance program management, will showcase a range of ... National Association for Assisted Living (NCAL) Convention and Expo to be held October ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s to ... and tested to meet the highest standard. , These products are also: ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... a leader in post-acute health care, have expanded their existing home health joint ... Health. , AccentCare has been operating a joint venture home health company with ...
(Date:10/12/2017)... ... ... HMP , a leader in healthcare events and education, today announced that ... ‘Best B-to-B Healthcare Website.’ Winners were announced during the Eddie & Ozzie Awards luncheon ... editorial and design excellence across a range of sectors. This year’s program included the ...
Breaking Medicine News(10 mins):